Cronograma de promoção BioMarin Pharmaceutical
Parâmetros básicos
Nota
Subestimação
Nome | Significado | Nota |
P/S | 4.51 | 3 |
P/BV | 2.28 | 6 |
P/E | 30.16 | 5 |
Eficiência
Nome | Significado | Nota |
ROA | 6.17 | 2 |
ROE | 8.05 | 3 |
ROIC | 0.79 | 1 |
Dividendos
Nome | Significado | Nota |
Rendimento de dividendos | 0 | 0 |
DSI | 0 | 0 |
Crescimento médio dos dividendos | 0 | 0 |
Obrigação
Nome | Significado | Nota |
Debt/EBITDA | 0.9265 | 9 |
Debt/Ratio | 0.0862 | 10 |
Debt/Equity | 0.2352 | 10 |
Impulso de crescimento
Nome | Significado | Nota |
Receita, % | 53.44 | 7 |
Ebitda, % | -11125.9 | 0 |
EPS, % | -51.56 | 0 |
paper.price.prices
Preço | Common.min. | Common.max. | Mudar | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 57.28 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 56.65 $ | 0 $ | 0 $ | +1.11 % | 0 % | 0 % |
common.calendar.number_days.30d | 58.01 $ | 0 $ | 0 $ | -1.26 % | 0 % | 0 % |
common.calendar.number_days.90d | 59.43 $ | 55.27 $ | 63.69 $ | -3.62 % | 0 % | 0 % |
common.calendar.number_days.180d | 62.87 $ | 55.27 $ | 72.83 $ | -8.89 % | 0 % | 0 % |
common.calendar.number_days.1y | 90.46 $ | 55.27 $ | 93.84 $ | -36.68 % | 0 % | 0 % |
common.calendar.number_days.3y | 89.02 $ | 55.27 $ | 117.27 $ | -35.65 % | 0 % | 0 % |
common.calendar.number_days.5y | 78.74 $ | 55.27 $ | 122.04 $ | -27.25 % | 0 % | 0 % |
common.calendar.number_days.10y | 81.38 $ | 55.27 $ | 143.78 $ | -29.61 % | 0 % | 0 % |
common.calendar.number_days.ytd | 61.58 $ | 55.27 $ | 72.83 $ | -6.98 % | 0 % | 0 % |
Negociação de informações privilegiadas
Principais proprietários
Contido em ETF
ETF | Compartilhar, % | Rentabilidade para o ano, % | Comissão, % |
VictoryShares Nasdaq Next 50 ETF | 1.38305 | 4.94 | 0.18 |
iShares Evolved U.S. Innovative Healthcare ETF | 1.35 | 0.000586 | 0.18 |
Future Tech ETF | 1.30612 | 479.5 | 0.35 |
Principal Healthcare Innovators ETF | 1.30612 | -3.92 | 0.35 |
IQ Engender Equality ETF | 1.03522 | 3.37 | 0.45 |
GraniteShares XOUT U.S. Large Cap ETF | 0.86381 | -24.16 | 0.60 |
Syntax Stratified MidCap ETF | 0.34133 | -0.3413 | 0.35 |
iShares Morningstar Mid-Cap Growth ETF | 0.24673 | 450.65 | 0.06 |
iShares Morningstar Mid-Cap ETF | 0.12333 | 245.03 | 0.04 |
iShares Morningstar Large-Cap Growth ETF | 0.05463 | 245.22 | 0.04 |
iShares Morningstar Large-Cap ETF | 0.0266 | 186.3 | 0.03 |
Columbia U.S. ESG Equity Income ETF | 0.02348 | -4.51 | 0.35 |
0,67 | 131,84 | 0,25 |
---|
Empresas semelhantes
Gestão da empresa
Supervisor | Cargo | Pagamento | Ano de nascimento |
Mr. Brian R. Mueller | CFO & Executive VP | 1.15M | 1974 (51 ano) |
Mr. George Eric Davis | Executive VP, Chief Legal Officer, General Counsel & Secretary | 1.23M | 1971 (54 ano) |
Ms. Erin Burkhart | Group VP & Chief Accounting Officer | N/A | 1979 (46 anos) |
Mr. Alexander Hardy | President, CEO & Director | N/A | 1969 (56 anos) |
Dr. C. Greg Guyer Ph.D. | Executive VP & CTO | 1962 (63 ano) | |
Dr. Kevin Eggan Ph.D. | Chief Scientific Officer & Senior VP of Research and Early Development | ||
Traci McCarty | Group Vice President of Investor Relations | ||
Ms. Humaira Serajuddin | Senior VP & Chief Marketing Officer | ||
Ms. Amy Wireman | Executive VP & Chief People Officer |
Informações da empresa
Site: http://www.biomarin.com
Sobre a empresa BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. — американская биотехнологическая компания со штаб-квартирой в Сан-Рафаэле, Калифорния . У него есть офисы и помещения в США , Южной Америке , Азии и Европе . Основным направлением деятельности и исследованиями BioMarin является заместительная терапия ферментами (ФЗТ). BioMarin была первой компанией, которая предоставила терапевтические средства для лечения мукополисахаридоза типа I (MPS I), производя ларонидазу ( Aldurazyme , коммерциализируется Genzyme Corporation). BioMarin также была первой компанией, которая начала предлагать препараты для лечения фенилкетонурии.